Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
News|Articles|April 2, 2025
Psychiatry Month in Review: March 2025
Author(s)Chelsie Derman
This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.
Advertisement
Advertisement
March brought important developments in mental health research. A meta-analysis confirmed that GLP-1 receptor agonists do not increase the risk of suicide or self-harm, easing concerns around their safety in managing diabetes and obesity. Meanwhile, a study on daily discrimination highlighted its strong link to depression and anxiety, with marginalized groups facing greater risks. Both studies underscore the need for ongoing research and more targeted care in mental health treatment.
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
Advertisement
Advertisement